Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)Christoph Rochlitz, Khalil Zaman, Stefanie Lerch et al.|Annals of Oncology|2010Cited by 26